SCHEMBL17493473

SCHEMBL17493473

CN(C)S(C)(=N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31381745 0.96
SCHEMBL48217 0.73
SCHEMBL24899710 0.72
SCHEMBL22266059 0.72
SCHEMBL1461465 0.71
SCHEMBL23241 0.70
Hydrochloric Acid SCHEMBL8888872 0.70
Potassium SCHEMBL11007396 0.67
SCHEMBL11007389 0.67
SCHEMBL15695396 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025085848-A1 ANTIBACTERIAL COMPOUNDS ARREPATH, INC. (US) 2025-04-24 WO disclosed
WO-2023220034-A1 ALKALI METAL PF 6 SALT STABILIZATION IN CARBONATE SOLUTIONS SILATRONIX, INC. (US) 2023-11-16 WO disclosed
EP-4198034-A1 BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Tuojie Biotech (Shanghai) Co., Ltd. (CN) 2023-06-21 EP disclosed
US-20220227707-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2022-07-21 US disclosed
EP-3914583-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY Novartis AG (CH) 2021-12-01 EP disclosed
EP-3240093-B1 SECONDARY BATTERY, BATTERY PACK, ELECTRIC VEHICLE, POWER STORAGE SYSTEM, ELECTRIC TOOL, AND ELECTRONIC APPARATUS MURATA MANUFACTURING CO (JP) 2020-08-19 EP disclosed
WO-2020154321-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-07-30 WO disclosed
WO-2020154321-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-07-30 WO disclosed
EP-3180338-B1 AZABENZIMIDAZOLE DERIVATIVES AS AMP PROTEIN KINASE AGONISTES BOEHRINGER INGELHEIM INT (DE) 2018-05-09 EP disclosed
EP-3240093-A1 SECONDARY BATTERY, BATTERY PACK, ELECTRIC VEHICLE, POWER STORAGE SYSTEM, ELECTRIC TOOL, AND ELECTRONIC APPARATUS Sony Corporation (JP) 2017-11-01 EP disclosed
EP-3180338-A1 AZABENZIMIDAZOLE DERIVATIVES AS AMP PROTEIN KINASE AGONISTES Boehringer Ingelheim International GmbH (DE) 2017-06-21 EP disclosed
US-9422312-B2 Azabenzimidazole derivatives BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-08-23 US disclosed
US-9422312-B2 Azabenzimidazole derivatives BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-08-23 US disclosed
US-9422312-B2 Azabenzimidazole derivatives BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-08-23 US disclosed
WO-2016023789-A1 AZABENZIMIDAZOLE DERIVATIVES AS AMP PROTEIN KINASE AGONISTES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-02-18 WO disclosed
US-20160039846-A1 AZABENZIMIDAZOLE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-02-11 US disclosed